These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324 [Abstract] [Full Text] [Related]
8. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW, Barillari G. J Clin Pharm Ther; 2014 Apr 21; 39(2):118-35. PubMed ID: 24383983 [Abstract] [Full Text] [Related]
9. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E. Thromb Res; 2014 Oct 21; 134(4):774-82. PubMed ID: 25037495 [Abstract] [Full Text] [Related]
10. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Dobesh PP, Fanikos J. Drugs; 2014 Nov 21; 74(17):2015-32. PubMed ID: 25300410 [Abstract] [Full Text] [Related]
15. Rivaroxaban for the prevention and treatment of venous thromboembolism. Turpie AG. Fundam Clin Pharmacol; 2012 Feb 21; 26(1):33-8. PubMed ID: 21851388 [Abstract] [Full Text] [Related]
16. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban]. Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero García I. Farm Hosp; 2009 Feb 21; 33(3):125-33. PubMed ID: 19712596 [Abstract] [Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Hellwig T, Gulseth M. Ann Pharmacother; 2013 Nov 21; 47(11):1478-87. PubMed ID: 24259602 [Abstract] [Full Text] [Related]